SYBX stock is making solid movement after Synlogic Inc (NASDAQ:SYBX) announced an $80 million equity investment from Ginkgo Bioworks.
Ginkgo’s Investment is Key for SynlogicAs one of the leading biopharmaceutical companies, Synlogic Inc (SYBX) makes use of synthetic biology to genetically engineer living medicines. Most recently, the company has inked an agreement with Boston biotech start-up, Gingko Bioworks.
The partnership between the two aims at expansion and overall development of Synlogic through making use of Ginkgo’s cell programming platform.
Under the arrangement, Ginkgo Bioworks is supposed to invest nearly $80 million ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.